A perspective on multi-target drug discovery and design for complex diseases.

Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. · 2018

Read A perspective on multi-target drug discovery and design for complex diseases. by Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5770353.txt.

Introduction

Ramsay and co-authors offer a perspective on drugs built to hit several targets at once. Complex diseases such as Alzheimer disease, Parkinson disease, and cancer rarely have one cause. Modern discovery can screen millions of compounds against many targets before any lab test. Validated targets must come first.

The piece focuses on the molecular and computer methods behind such design. It explains how medicinal chemists pick and test multi-target leads. Work in dishes and in animals still decides which leads survive. The authors call for close teamwork between chemists and clinical scientists throughout.

Catalog record

CREATORRamsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE70 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5770353

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A perspective on multi-target drug discovery and design for complex diseases By Rona R Ramsay, Marija R Popovic-Nikolic, Katarina Nikolic, Elisa Uliassi, Maria Laura Bolognesi Published in: Clinical and Translational Medicine DOI: 10.1186/s40169-017-0181-2 ABSTRACT Abstract Diseases of infection, of neurodegeneration (such as Alzheimer’s and Parkinson’s diseases), and of malignancy (cancers) have complex and varied causative factors. Modern drug discovery has the power to identify potential modulators for multiple targets from millions of compounds. Computational approaches allow the determination of the association of each compound with its target before chemical synthesis and biological testing is done. These approaches depend on the prior identification of clinically and biologically validated targets. This Perspective will focus on the molecular and computational approaches that underpin drug design by medicinal chemists to promote understanding and collaboration with clinical scientists. Keywords: Multi-target drugs, Neurodegeneration, Cancer, Cheminformatics, Virtual screening, Biological assays INTRODUCTION Drug discovery in the 21st century has the disadvantage that it is very difficult to get new compounds into the clinic. The diseases where cures or at least treatments are sought are complex ones involving many potential defects in the structure, function, or regulation of the cells involved. Major targets that will be considered here are Alzheimer’s (AD) and Parkinson’s (PD) diseases of neurodegeneration, and cancer. Despite the complexity of causative factors that can lead to these disease states, the tools of modern drug discovery have the power to cover millions of compounds or fragments and determine their potential association with a target before specific chemical synthesis and biological testing is done. This perspective will focus on the molecular and computational approaches that underpin drug design by medicinal chemists. These approaches require the prior identification of clinically and biologically validated targets, and subsequent experimental testing both in vitro and in vivo. The success of drug design for complex diseases depends on an interdisciplinary and collaborative approach, and on scientists and clinicians who are willing to communicate and work together throughout the process. DESIGNING MULTI-TARGET DRUGS FOR COMPLEX DISEASES The transition from the single-target to the multi-target concept for drug design Traditionally drugs have been designed with the aim of targeting a single biological entity, usually a protein (the so-called “on-target”), with high selectivity to avoid any unwanted effects arising from mis-targeting other biological targets (“off-targets”). On this basis, the concept of drugs interacting with multiple targets has long been flagged as undesirable, as it was inherently associated with adverse side effects. However, the complexity of the current incurable pathologies has clearly demonstrated that such single-target drugs are inadequate to achieve a therapeutic effect [1, 2]. In parallel, we have learned that molecules hitting more than one target may possess in principle a safer profile compared to single-targeted ones [1, 2]. Building on such accumulating evidence, the concept of multi-target drugs has made rapid and spectacular progress from being an emerging paradigm when first enunciated at the beginning of 2000 [3–5], to one of the hottest topics in drug discovery in 2017. Indeed, in the years, these concepts have triggered the interest of the drug discovery community both in academia and pharmaceutical companies to such a point that a plethora of multi-target drugs are already available on the market. The analysis of FDA-approved new molecular entities (NMEs) from 2015 to 2017 As a clear proof of such translational success of multi-target drugs into the clinic, we have performed an analysis of the US Food and Drug Administration (FDA)-approved new molecular entities (NMEs) from 2015 to 2017 (status September 2017), following a similar analysis (from 2000 to 2015) made by Lin et al. [6]. The 101 new NMEs on FDA.gov approved over this triennium were classified into NME categories (small molecules, biologics, therapeutic combinations and diagnostics). By using the DrugBank database, which compiles information on approved drugs, together with their target(s) and mechanism(s) of action (MoA), the small molecules have been further analyzed and subdivided into single-target and multi-target drugs. As depicted in Fig. 1, biotech drugs (proteins, peptides and monoclonal antibodies) represent 31% of the novel NMEs, nearly approaching the number of single-target drugs (34%). This clearly reflects the recent increased pharma interest in discovery of biologics [7], which build on the premise of a personalized treatment [8]. [Figure: Distribution of the new molecular entities (NMEs) approved from 2015 to 2017 (status September 2017), organized according to the different classes of NMEs] Notwithstanding the increase of approved biologics in recent years, small molecules, both single-targeted and multi-targeted ones, continue to contribute. Although the number of single-target small molecules (34%) is still greater than that of multi-target drugs (21%), the latter keeps increasing compared to previous years (16%) [6, 9]. However, if we broaden our view and reason in terms of general polypharmacology, we can add together the 21% of multi-target drugs and the newly approved therapeutic combinations (10%). In this way, the total percentage (31%) approaches that of single-target drugs (34%). This unequivocally supports the attractiveness of polypharmacological strategies, especially in certain therapeutic areas, such as anti-infective, nervous system, and anti-neoplastic agents (Fig. 2). [Figure: The 21 multi-target drugs and 10 therapeutic combinations approved in 2015–2017 organized according to their Anatomical Therapeutic Chemical (ATC) Classification System] Examples of multi-target drugs for complex diseases With regards to anti-infectives, daclatasvir is one of the last approved (2015) non-interferon based agents against hepatitis C virus (HCV), developed to selectively target one of the key viral proteins involved in the HCV replication, i.e. nonstructural 5A (NS5A) phosphoprotein [10]. Despite the high effectiveness, several combination therapies have been approved since January 2016 because drug-resistance is an already established phenomenon [10]. These combinations were all conceived based on the prototypical polypharmacology hypothesis that targeting two different nodes of HCV replication may exhibit superior antiviral activity compared to single drugs and reduced resistance [11]. These combinations include: (i) elbasvir, a NS5A inhibitor, combined with grazoprevir, a NS3/4A protease inhibitor, (ii) the combination of sofosbuvir, a nucleotide analogue NS5B polymerase inhibitor, and velpatasvir, a NS5A inhibitor, and (iii) the fixed-dose combination of glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor [11]. Nervous system application of polypharmacology has led to approval of four multi-target drugs. Recently, an increased number of multi-target drugs have been developed to treat schizophrenia and major depressive disorders [12–14]. The main strategy for treatment of schizophrenia is based on antagonizing dopamine D2, serotonin 5-HT2A and α1-adrenergic receptors [15]. Incorporating effects at these broad targets has the objective of either improving antipsychotic efficacy or mitigating adverse effects. With these concepts in mind, starting from the arylpiperazine substructure as suitable scaffold for achieving a fine balancing of D2, 5-HT1A and 5-HT2A receptors activities, the prototype of the third-generation of antipsychotics, aripiprazole, launched into the market in 2015, was the first designed serotonin-dopamine activity modulator (SDAM). However, it also displayed unwanted side effects, probably arising from a sustained interaction with post-synaptic D2 receptors. Thus, brexpiprazole was licensed on October 2015 as a novel D2 and 5-HT1A partial agonist, with less intrinsic activity at D2 receptors and more balanced activities at 5-HT2A, 5-HT1A, and α1B receptor subtypes than aripiprazole [15]. Another excellent example is cariprazine, approved by the FDA in September 2015 for the treatment of schizophrenia and bipolar disorders. Similarly to the above

Read the complete text